Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms.
human papillomavirus
risk
second primary cancer
Journal
MedComm
ISSN: 2688-2663
Titre abrégé: MedComm (2020)
Pays: China
ID NLM: 101769925
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
23
05
2020
revised:
01
11
2020
accepted:
03
11
2020
entrez:
12
11
2021
pubmed:
13
11
2021
medline:
13
11
2021
Statut:
epublish
Résumé
Comprehensive studies in second primary cancer (SPC) after the initial primary human papillomavirus (HPV)-related cancer still remain warranted. We aimed to analyze the incidence and risk factors of SPC after HPV-related cancer. We identified 86 790 patients diagnosed with initial primary HPV-related cancer between 1973 and 2010 in the SEER database. Standardized incidence ratio (SIR) and cumulative incidence were calculated to assess the risk of SPC after HPV-related cancer. The SIR of SPC after HPV-related cancer was 1.60 (95% confidence interval [CI], 1.55-1.65) for male and 1.25 (95% CI, 1.22-1.28) for female. SIR of second primary HPV-related cancer (7.39 [95% CI, 6.26-8.68] male and 4.35 [95% CI, 4.04-4.67] female) was significantly higher than that of HPV-unrelated cancer (1.54 [95% CI, 1.49-1.60] male and 1.16 [95% CI, 1.13-1.19] female). The 5-year cumulative incidence of SPC was 7.22% (95% CI, 6.89-7.55%) for male and 3.72% (95% CI, 3.58-3.88%) for female. Risk factors for SPC included being married and having initial primary cancer (IPC) diagnosed at earlier stage for both genders, and IPC diagnosed at older age as well as surgery performed for female. Patients diagnosed with HPV-related cancer are more likely to develop another primary cancer, compared with the age-specific reference population.
Identifiants
pubmed: 34766131
doi: 10.1002/mco2.43
pii: MCO243
pmc: PMC8491207
doi:
Types de publication
Journal Article
Langues
eng
Pagination
400-409Informations de copyright
© 2020 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
JAMA. 2007 Feb 28;297(8):813-9
pubmed: 17327523
Front Oncol. 2016 Apr 11;6:82
pubmed: 27148474
Oncotarget. 2017 Jun 16;8(39):66352-66359
pubmed: 29029517
BMC Cancer. 2014 Dec 17;14:968
pubmed: 25515630
Cancer. 1977 Oct;40(4 Suppl):1892-8
pubmed: 907991
Gynecol Oncol. 2001 Aug;82(2):269-72
pubmed: 11531278
Mod Pathol. 2019 Jul;32(8):1189-1196
pubmed: 30911077
JAMA Oncol. 2017 Jun 1;3(6):810-816
pubmed: 28114440
Br J Cancer. 2008 Aug 5;99(3):404-7
pubmed: 18648363
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
J Infect Dis. 2011 Jan 1;203(1):49-57
pubmed: 21148496
J Natl Cancer Inst. 2004 Jan 21;96(2):99-106
pubmed: 14734699
BJOG. 2014 May;121(6):728-38; discussion 739
pubmed: 24148762
J Clin Oncol. 2011 Feb 20;29(6):739-46
pubmed: 21189382
Zentralbl Chir. 2012 Dec;137(6):565-74
pubmed: 22426967
BMC Infect Dis. 2005 Nov 08;5:102
pubmed: 16274490
J Clin Pathol. 2004 May;57(5):449-55
pubmed: 15113849
Indian J Hum Genet. 2011 Sep;17(3):132-44
pubmed: 22345983
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Cancer Causes Control. 2009 May;20(4):449-57
pubmed: 19082746
Front Immunol. 2020 Feb 18;11:188
pubmed: 32133000
Cancer Causes Control. 2013 Dec;24(12):2169-76
pubmed: 24101363
Int J Cancer. 2009 Apr 1;124(7):1626-36
pubmed: 19115209
J Biomed Sci. 2016 Nov 4;23(1):75
pubmed: 27809842
J Clin Oncol. 1999 May;17(5):1391-6
pubmed: 10334523
J Clin Oncol. 2008 Feb 1;26(4):612-9
pubmed: 18235120
Anticancer Res. 2007 Jul-Aug;27(4C):2697-704
pubmed: 17695435
Cancer. 2004 Jul 15;101(2):281-8
pubmed: 15241824
MedComm (2020). 2020 Dec 03;1(3):400-409
pubmed: 34766131
Nat Genet. 2013 Aug;45(8):918-22
pubmed: 23817570
Medicine (Baltimore). 2015 Oct;94(43):e1803
pubmed: 26512575
Cancer. 2014 Dec 15;120(24):3987-93
pubmed: 25116228
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Int J Gynecol Cancer. 2012 Sep;22(7):1208-13
pubmed: 22854653
Endocr Relat Cancer. 2012 Feb 13;19(1):95-9
pubmed: 22194442
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Oral Implantol (Rome). 2017 Nov 30;10(3):209-220
pubmed: 29285322
Oncol Res Treat. 2016;39(9):501-6
pubmed: 27614953
Lancet Oncol. 2006 Feb;7(2):149-56
pubmed: 16455479
Laryngoscope. 2014 Jan;124(1):131-8
pubmed: 23832649
JAMA Netw Open. 2018 Sep 7;1(5):e181999
pubmed: 30646145
Lancet. 2013 Sep 7;382(9895):889-99
pubmed: 23618600
Acta Oncol. 2018 Feb;57(2):239-243
pubmed: 29057703
Int J Cancer. 2011 Jun 15;128(12):2892-7
pubmed: 20725995
Am J Surg Pathol. 2005 Oct;29(10):1367-72
pubmed: 16160480
World J Gastrointest Surg. 2016 Jan 27;8(1):41-51
pubmed: 26843912
Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2550-6
pubmed: 16284377
Oncotarget. 2017 Oct 9;8(56):96419-96432
pubmed: 29221217
JAMA. 2008 May 28;299(20):2423-36
pubmed: 18505952
JAMA. 2007 Aug 15;298(7):805-6
pubmed: 17699015
Anticancer Res. 2016 Jul;36(7):3511-4
pubmed: 27354616
Clin Cancer Res. 2005 Apr 15;11(8):2862-7
pubmed: 15837733
BMC Urol. 2005 Nov 24;5:15
pubmed: 16307686
Oncologist. 2010;15(9):994-1001
pubmed: 20798198
Br J Cancer. 2019 Jan;120(2):256-268
pubmed: 30482913
JAMA. 2007 Aug 15;298(7):743-53
pubmed: 17699008
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Ann Diagn Pathol. 2015 Dec;19(6):418-22
pubmed: 26321154
Eur J Surg Oncol. 2008 Jul;34(7):765-70
pubmed: 18160246
PLoS Genet. 2017 Aug 14;13(8):e1006866
pubmed: 28806749
Prev Med. 2016 Sep;90:52-8
pubmed: 27370167